Research press release


Nature Medicine

Pre-eclampsia may be an autoimmune disease



これまでの研究で、子癇前症の女性は1a型アンジオテンシンII受容体(AT1)に結合、活性化する自己抗体をもつことが明らかになっている。この受容体は血圧の調節にかかわることが知られている。Y Xiaたちは、妊娠中のマウスにAT1に対する抗体を注射すると、前述のような症状の一部が現れることを明らかにした。この子癇前症に類似した症状は、抗体と一緒にAT1受容体のアンタゴニストであるロサルタンか、この抗体を中和する作用をもつAT1由来のペプチドを注射することによって、防ぐことができたという。

A pre-eclampsia-like syndrome can be induced in mice by giving them autoantibodies isolated from humans with the disease, reports a study published this week in Nature Medicine. This finding may have implications in the diagnosis and treatment of pre-eclampsia.

Pre-eclampsia affects about 5% of pregnancies and is a leading cause of maternal and neonatal morbidity in the world. The clinical hallmarks of this disorder include hypertension, vascular dysfunction and placental defects, and it can lead to cerebral haemorrhage and renal failure. There is no effective treatment owing to the poor understanding of the disease.

Some studies have shown that women with pre-eclampsia have autoantibodies that bind and activate a receptor called angiotensin II type 1a (AT1), which is known to participate in blood pressure regulation. Yang Xia and colleagues show that some of these features appear in pregnant mice after injection with antibodies against the AT1 receptor. They managed to prevent this pre-eclampsia-like syndrome by co-injection with the AT1 receptor antagonist losartan or with an AT1 receptor?derived peptide capable of neutralizing the antibody.

doi: 10.1038/nm.1856


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。